Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.

Clinical pharmacology and therapeutics - 1 May 1996

Kévorkian J P, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer H K, Peraldi M N, Eichelbaum M, Jaillon P, Funck-Brentano C

Abstract excerpt

OBJECTIVES: To examine whether the variability of CYP2D6 activity in patients with chronic renal failure can be assessed, particularly among subjects with the extensive metabolizer phenotype, by use of standard in vivo indexes of CYP2D6 activity derived from oral administration of dextromethorphan and sparteine. METHODS: A single 100 mg oral dose of sparteine and a single 40 mg oral dose of dextromethorphan were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Dose-Response Relationship, Drug

Share to Kidney Failure, Chronic

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Regression Analysis

Source

Identifiers

PMID: 8646830
DOI: 10.1016/S0009-9236(96)90187-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.PMID 8646830Read ↗

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.Semantic proximity Read ↗

Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.Semantic proximity Read ↗

Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.Semantic proximity Read ↗

Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.Semantic proximity Read ↗

Dextromethorphan metabolic phenotyping in a Chinese population.Semantic proximity Read ↗

Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.Semantic proximity Read ↗

Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.